BAKER BROS. ADVISORS LP
Filing Date
Global Rank
#316
/ 8,700
▲ 22
Top Industry
Biotechnology
94.9%
Period ended 2 months ago
Filed Aug 14, 2026 · 29d
26 quarters · since Mar 2020
Portfolio Concentration
83 tracked positions · as of Jun 30, 2026 · Δ vs Mar 31, 2026Top Position
17.5%
+0.8 pts
Top 5
52.2%
+1.4 pts
Top 10
73.1%
−0.8 pts
HHI
769
Diversified−1
Portfolio Trend
26 quarters · across all stocks
Sector Breakdown
As of Jun 30, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $19,885,163,299 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased
16 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| ABCL | AbCellera Biologics Inc. | +2,736,200 | 33,012,138 | $259,145,283 | |
| VSTM | Verastem, Inc. | +1,914,581 | 2,499,338 | $9,547,471 | |
| RVMD | Revolution Medicines, Inc. | +1,888,000 | 11,443,357 | $2,143,111,898 | |
| RLAY | Relay Therapeutics, Inc. | +1,666,666 | 2,826,783 | $52,889,109 | |
| INSM | INSMED Inc | +1,375,000 | 8,796,111 | $937,841,354 | |
| IDYA | IDEAYA Biosciences, Inc. | +1,063,515 | 5,010,030 | $186,723,818 | |
| CLDX | Celldex Therapeutics, Inc. | +517,241 | 1,182,611 | $44,004,955 | |
| RCUS | Arcus Biosciences, Inc. | +429,195 | 844,816 | $26,045,677 | |
| VRDN | Viridian Therapeutics, Inc.\DE | +411,347 | 2,383,025 | $43,776,169 | |
| DSGN | Design Therapeutics, Inc. | +92,452 | 2,678,430 | $38,756,882 | |
| INCY | Incyte Corp | +17,918 | 30,762,330 | $3,487,217,728 | |
| ACAD | Acadia Pharmaceuticals Inc | +16,214 | 42,912,904 | $1,085,696,471 | |
| KNSA | Kiniksa Pharmaceuticals International, plc | +8,397 | 2,834,643 | $181,275,419 | |
| DNLI | Denali Therapeutics Inc. | +2,641 | 3,734,336 | $96,047,121 | |
| ONC | BeOne Medicines Ltd. | +2,514 | 8,801,567 | $2,508,182,547 | |
| MDGL | Madrigal Pharmaceuticals, Inc. | +1,430 | 2,143,131 | $1,150,754,190 | |
| No positions match the current search. | |||||
Trimmed
Positions the filer reduced
7 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| CERS | Cerus Corp | −3,612,914 | 6,395,431 | $18,674,658 | |
| SMMT | Summit Therapeutics Inc. | −3,604,715 | 32,786,348 | $477,697,090 | |
| EWTX | Edgewise Therapeutics, Inc. | −2,874,221 | 3,701,719 | $150,400,842 | |
| IMTX | Immatics N.V. | −1,408,128 | 9,508,565 | $96,321,763 | |
| JBIO | Jade Biosciences, Inc. | −410,711 | 1,230,426 | $27,340,065 | |
| ROIV | Roivant Sciences Ltd. | −150,892 | 4,716,831 | $166,928,649 | |
| IMVT | Immunovant, Inc. | −22,661 | 5,435,220 | $209,419,026 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarter
8 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| FTH | Faeth Therapeutics, Inc. | 1,286,411 | $32,160,275 | |
| CYTK | Cytokinetics Inc | 211,267 | $17,997,835 | |
| NTLA | Intellia Therapeutics, Inc. | 930,232 | $15,739,525 | |
| PBLS | Parabilis Medicines, Inc. | 500,000 | $13,685,000 | |
| AVLN | Avalyn Pharma Inc. | 350,000 | $11,522,000 | |
| TNGX | Tango Therapeutics, Inc. | 333,333 | $10,419,989 | |
| AVTX | Avalo Therapeutics, Inc. | 550,000 | $10,164,000 | |
| IMNM | Immunome Inc. | 55,306 | $1,171,934 | |
| No positions match the current search. | ||||
Sold Out
Positions the filer fully exited
8 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| ABVX | Abivax S.A. | 875,796 | $97,519,884 | |
| SYRE | Spyre Therapeutics, Inc. | 1,000,000 | $50,440,000 | |
| IMCR | Immunocore Holdings plc | 734,397 | $22,142,069 | |
| CTNM | Contineum Therapeutics, Inc. | 1,420,838 | $18,556,144 | |
| ARGX | Argenx SE | 25,174 | $18,383,313 | |
| CMPS | COMPASS Pathways plc | 2,344,720 | $12,966,301 | |
| PHVS | Pharvaris N.V. | 375,000 | $10,593,750 | |
| CNTA | Centessa Pharmaceuticals plc | 670,751 | $0 | |
| No positions match the current search. | ||||
83 tracked positions ·
$19,885,163,299 total
· filing declares
84 positions · $19,955,238,553
· as of Jun 30, 2026
Showing 1–50
of 83 positions by value
· page 1 of 2
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| INCY |
Incyte Corp
Healthcare
|
Added | 30,762,330 | $3,487,217,728 | 17.54% | |
| ONC |
BeOne Medicines Ltd.
Healthcare
|
Added | 8,801,567 | $2,508,182,547 | 12.61% | |
| RVMD |
Revolution Medicines, Inc.
Healthcare
|
Added | 11,443,357 | $2,143,111,898 | 10.78% | |
| MDGL |
Madrigal Pharmaceuticals, Inc.
Healthcare
|
Added | 2,143,131 | $1,150,754,190 | 5.79% | |
| ACAD |
Acadia Pharmaceuticals Inc
Healthcare
|
Added | 42,912,904 | $1,085,696,471 | 5.46% | |
| KYMR |
Kymera Therapeutics, Inc.
Healthcare
|
Held | 8,657,242 | $992,725,940 | 4.99% | |
| INSM |
INSMED Inc
Healthcare
|
Added | 8,796,111 | $937,841,354 | 4.72% | |
| CELC |
Celcuity Inc.
Healthcare
|
Held | 7,915,792 | $828,150,159 | 4.16% | |
| KOD |
Kodiak Sciences Inc.
Healthcare
|
Held | 19,919,186 | $776,051,486 | 3.90% | |
| RYTM |
Rhythm Pharmaceuticals, Inc.
Healthcare
|
Held | 5,604,483 | $622,265,747 | 3.13% | |
| PRAX |
Praxis Precision Medicines, Inc.
Healthcare
|
Held | 1,753,198 | $586,953,158 | 2.95% | |
| ALKS |
Alkermes plc.
Healthcare
|
Held | 10,012,267 | $524,642,790 | 2.64% | |
| SMMT |
Summit Therapeutics Inc.
Healthcare
|
Reduced | 32,786,348 | $477,697,090 | 2.40% | |
| GRAL |
GRAIL, Inc.
Healthcare
|
Held | 4,028,614 | $275,033,477 | 1.38% | |
| ABCL |
AbCellera Biologics Inc.
Healthcare
|
Added | 33,012,138 | $259,145,283 | 1.30% | |
| IMVT |
Immunovant, Inc.
Healthcare
|
Reduced | 5,435,220 | $209,419,026 | 1.05% | |
| IDYA |
IDEAYA Biosciences, Inc.
Healthcare
|
Added | 5,010,030 | $186,723,818 | 0.94% | |
| KNSA |
Kiniksa Pharmaceuticals International, plc
Healthcare
|
Added | 2,834,643 | $181,275,419 | 0.91% | |
| ROIV |
Roivant Sciences Ltd.
Healthcare
|
Reduced | 4,716,831 | $166,928,649 | 0.84% | |
| ARWR |
Arrowhead Pharmaceuticals, Inc.
Healthcare
|
Held | 1,992,783 | $162,431,742 | 0.82% | |
| IONS |
Ionis Pharmaceuticals Inc
Healthcare
|
Held | 2,047,727 | $162,364,273 | 0.82% | |
| EWTX |
Edgewise Therapeutics, Inc.
Healthcare
|
Reduced | 3,701,719 | $150,400,842 | 0.76% | |
| REPL |
Replimune Group, Inc.
Healthcare
|
Held | 11,045,336 | $122,271,869 | 0.61% | |
| NRIX |
Nurix Therapeutics, Inc.
Healthcare
|
Held | 4,658,556 | $113,016,568 | 0.57% | |
| STOK |
Stoke Therapeutics, Inc.
Healthcare
|
Held | 3,336,697 | $109,176,725 | 0.55% | |
| GLUE |
Monte Rosa Therapeutics, Inc.
Healthcare
|
Held | 4,345,736 | $105,166,811 | 0.53% | |
| IMTX |
Immatics N.V.
Healthcare
|
Reduced | 9,508,565 | $96,321,763 | 0.48% | |
| DNLI |
Denali Therapeutics Inc.
Healthcare
|
Added | 3,734,336 | $96,047,121 | 0.48% | |
| CRNX |
Crinetics Pharmaceuticals, Inc.
Healthcare
|
Held | 2,351,465 | $87,991,820 | 0.44% | |
| DNTH |
Dianthus Therapeutics, Inc. /DE/
Healthcare
|
Held | 852,164 | $83,068,946 | 0.42% | |
| GPCR |
Structure Therapeutics Inc.
Healthcare
|
Held | 1,432,529 | $76,883,831 | 0.39% | |
| RAPP |
Rapport Therapeutics, Inc.
Healthcare
|
Held | 1,547,090 | $64,467,240 | 0.32% | |
| ALMS |
Alumis Inc.
Healthcare
|
Held | 2,012,500 | $56,631,750 | 0.28% | |
| PRLD |
Prelude Therapeutics Inc
Healthcare
|
Held | 10,123,824 | $53,959,981 | 0.27% | |
| RLAY |
Relay Therapeutics, Inc.
Healthcare
|
Added | 2,826,783 | $52,889,109 | 0.27% | |
| MIRM |
Mirum Pharmaceuticals, Inc.
Healthcare
|
Held | 445,975 | $52,210,293 | 0.26% | |
| BCYC |
Bicycle Therapeutics PLC
Healthcare
|
Held | 10,885,357 | $46,153,913 | 0.23% | |
| ELVN |
Enliven Therapeutics, Inc.
Healthcare
|
Held | 905,191 | $45,938,443 | 0.23% | |
| CLDX |
Celldex Therapeutics, Inc.
Healthcare
|
Added | 1,182,611 | $44,004,955 | 0.22% | |
| VRDN |
Viridian Therapeutics, Inc.\DE
Healthcare
|
Added | 2,383,025 | $43,776,169 | 0.22% | |
| DSGN |
Design Therapeutics, Inc.
Healthcare
|
Added | 2,678,430 | $38,756,882 | 0.19% | |
| TRDA |
Entrada Therapeutics, Inc.
Healthcare
|
Held | 5,072,730 | $37,335,292 | 0.19% | |
| FTH |
Faeth Therapeutics, Inc.
Healthcare
|
NEW | 1,286,411 | $32,160,275 | 0.16% | |
| AKTS |
Aktis Oncology, Inc.
Healthcare
|
Held | 996,351 | $32,112,392 | 0.16% | |
| NGNE |
Neurogene Inc.
Healthcare
|
Held | 991,691 | $31,188,681 | 0.16% | |
| JBIO |
Jade Biosciences, Inc.
Healthcare
|
Reduced | 1,230,426 | $27,340,065 | 0.14% | |
| TSHA |
Taysha Gene Therapies, Inc.
Healthcare
|
Held | 4,004,756 | $27,272,388 | 0.14% | |
| RCUS |
Arcus Biosciences, Inc.
Healthcare
|
Added | 844,816 | $26,045,677 | 0.13% | |
| IRON |
Disc Medicine, Inc.
Healthcare
|
Held | 349,657 | $25,573,912 | 0.13% | |
| ABSI |
Absci Corp
Healthcare
|
Held | 2,134,803 | $24,742,366 | 0.12% |
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.